JP7627393B2 - 白金耐性癌の治療 - Google Patents

白金耐性癌の治療 Download PDF

Info

Publication number
JP7627393B2
JP7627393B2 JP2019562653A JP2019562653A JP7627393B2 JP 7627393 B2 JP7627393 B2 JP 7627393B2 JP 2019562653 A JP2019562653 A JP 2019562653A JP 2019562653 A JP2019562653 A JP 2019562653A JP 7627393 B2 JP7627393 B2 JP 7627393B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
compound
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519652A (ja
Inventor
バナージ、ウダイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of JP2020519652A publication Critical patent/JP2020519652A/ja
Priority to JP2023018285A priority Critical patent/JP7658995B2/ja
Application granted granted Critical
Publication of JP7627393B2 publication Critical patent/JP7627393B2/ja
Priority to JP2025052922A priority patent/JP2025098190A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
JP2019562653A 2017-05-16 2018-05-16 白金耐性癌の治療 Active JP7627393B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023018285A JP7658995B2 (ja) 2017-05-16 2023-02-09 白金耐性癌の治療
JP2025052922A JP2025098190A (ja) 2017-05-16 2025-03-27 白金耐性癌の治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1707864.3A GB201707864D0 (en) 2017-05-16 2017-05-16 Platinum-reistant cancer treatment
GB1707864.3 2017-05-16
US201762513627P 2017-06-01 2017-06-01
US62/513,627 2017-06-01
PCT/IB2018/053428 WO2018211433A1 (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023018285A Division JP7658995B2 (ja) 2017-05-16 2023-02-09 白金耐性癌の治療

Publications (2)

Publication Number Publication Date
JP2020519652A JP2020519652A (ja) 2020-07-02
JP7627393B2 true JP7627393B2 (ja) 2025-02-06

Family

ID=59201547

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019562653A Active JP7627393B2 (ja) 2017-05-16 2018-05-16 白金耐性癌の治療
JP2023018285A Active JP7658995B2 (ja) 2017-05-16 2023-02-09 白金耐性癌の治療
JP2025052922A Pending JP2025098190A (ja) 2017-05-16 2025-03-27 白金耐性癌の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023018285A Active JP7658995B2 (ja) 2017-05-16 2023-02-09 白金耐性癌の治療
JP2025052922A Pending JP2025098190A (ja) 2017-05-16 2025-03-27 白金耐性癌の治療

Country Status (13)

Country Link
US (4) US20200352945A1 (https=)
EP (1) EP3624803A1 (https=)
JP (3) JP7627393B2 (https=)
KR (2) KR20240148941A (https=)
CN (1) CN110603042A (https=)
AR (1) AR111803A1 (https=)
AU (2) AU2018268400B2 (https=)
GB (1) GB201707864D0 (https=)
MX (2) MX2019013665A (https=)
NZ (1) NZ758037A (https=)
SG (1) SG11201909859RA (https=)
TW (1) TW201900176A (https=)
WO (1) WO2018211433A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55818A (fr) 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique
EP4347661A4 (en) * 2021-06-04 2025-06-18 ImmunoGen, Inc. TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA
WO2024097784A2 (en) * 2022-11-03 2024-05-10 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for treating refractory cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005509600A (ja) 2001-08-31 2005-04-14 ビーティージー・インターナショナル・リミテッド 抗癌シクロペンタ［ｇ］キナゾリン化合物
JP2011515384A (ja) 2008-03-18 2011-05-19 ビーティージー・インターナショナル・リミテッド リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体
JP2014513663A (ja) 2010-12-22 2014-06-05 オニックス ファーマシューティカルズ，インコーポレイティド 効率的なペプチドカップリングおよびシクロペンタ［ｇ］キナゾリン３ナトリウム塩の合成および単離でのそれらの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
US7528141B2 (en) * 2001-08-31 2009-05-05 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
EA201291302A1 (ru) 2010-07-19 2013-09-30 Оникс Фармасьютикалз, Инк. Синтез циклопентахиназолинов

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005509600A (ja) 2001-08-31 2005-04-14 ビーティージー・インターナショナル・リミテッド 抗癌シクロペンタ［ｇ］キナゾリン化合物
JP2011515384A (ja) 2008-03-18 2011-05-19 ビーティージー・インターナショナル・リミテッド リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体
JP2014513663A (ja) 2010-12-22 2014-06-05 オニックス ファーマシューティカルズ，インコーポレイティド 効率的なペプチドカップリングおよびシクロペンタ［ｇ］キナゾリン３ナトリウム塩の合成および単離でのそれらの使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ａｎ ｉｎｖｅｓｔｉｇａｔｏｒ－ｉｎｉｔｉａｔｅｄ ｐｈａｓｅ Ｉ ｓｔｕｄｙ ｏｆ ＯＮＸ－０８０１， ａ ｆｉｒｓｔ－ｉｎ ｃｌａｓｓ ａｌｐｈａ ｆｏｌａｔｅ ｒｅｃｅｐｔｏｒ ｔａｒｇｅｔｅｄ ｓｍａｌｌ ｍｏｌｅｃｕｌｅ ｔｈｙｍｉｄｙｌａｔｅ ｓｙｎｔｈａｓｅ ｉｎｈｉｂｉｔｏｒ ｉｎ ｓｏｌｉｄ ｔｕｍｏｒｓ．、ＡＳＣＯ Ｍｅｅｔｉｎｇ Ｌｉｂｒａｒｙ ［ｏｎｌｉｎｅ］、２０１７年，ｒｅｔｒｉｅｖｅｄ ｏｎ １３ Ｍａｙ ２０２２＜ＵＲＬ：ｈｔｔｐｓ：／／ｍｅｅｔｉｎｇｌｉｂｒａｒｙ．ａｓｃｏ．ｏｒｇ／ｒｅｃｏｒｄ／１４４５８１／ａｂｓｔｒａｃｔ＞
Ｃａｎｃｅｒ Ｒｅｓ．、２００５年、Ｖｏｌ．６５、Ｎｏ．２４、ｐ．１１７２１－１１７２８
Ｃａｎｃｅｒ Ｒｅｓ．、２００７年、Ｖｏｌ．６７、９＿Ｓｕｐｐｌｍｅｎｔ、３１９１
Ｃａｎｃｅｒ Ｒｅｓ．、２００８年、Ｖｏｌ．６８、９＿Ｓｕｐｐｌｍｅｎｔ、３２８９
Ｇｙｎｅｃｏ Ｏｎｃｏｌ．，２００８年、Ｖｏｌ．１０８、Ｎｏ．３、ｐ．６１９－６２６（Ｐａｇｅ１－１６）
Ｈｉｓｔｏｒｙ ｏｆ Ｃｈａｎｇｅｓ ｆｏｒ Ｓｔｕｄｙ： ＮＣＴ０２３６０３４５、Ｃｌｉｎｉｃａｌ Ｔｒｉａｌｓ．ｇｏｖ ａｒｃｈｉｖｅ ［ｏｎｌｉｎｅ］、２０１５年；ｒｅｔｒｉｅｖｅｄ ｏｎ １３ Ｍａｙ ２０２２＜ＵＲＬ：ｈｔｔｐｓ：／／ｃｌｉｎｉｃａｌｔｒｉａｌｓ．ｇｏｖ／ｃｔ２／ｈｉｓｔｏｒｙ／ＮＣＴ０２３６０３４５？Ｖ＿１＝Ｖｉｅｗ＃ＳｔｕｄｙＰａｇｅＴｏｐ＞

Also Published As

Publication number Publication date
MX2019013665A (es) 2020-01-13
AU2018268400B2 (en) 2024-05-16
US20200197402A1 (en) 2020-06-25
AR111803A1 (es) 2019-08-21
MX2023005295A (es) 2023-05-24
JP2025098190A (ja) 2025-07-01
US20210252001A1 (en) 2021-08-19
JP2020519652A (ja) 2020-07-02
US12128045B2 (en) 2024-10-29
JP2023065427A (ja) 2023-05-12
US20250152587A1 (en) 2025-05-15
AU2024205462A1 (en) 2024-08-22
CA3062552A1 (en) 2018-11-22
CN110603042A (zh) 2019-12-20
EP3624803A1 (en) 2020-03-25
GB201707864D0 (en) 2017-06-28
KR20200003811A (ko) 2020-01-10
US11026948B2 (en) 2021-06-08
AU2024205462B2 (en) 2025-09-25
KR20240148941A (ko) 2024-10-11
JP7658995B2 (ja) 2025-04-08
NZ758037A (en) 2026-01-30
WO2018211433A1 (en) 2018-11-22
US20200352945A1 (en) 2020-11-12
TW201900176A (zh) 2019-01-01
SG11201909859RA (en) 2019-11-28
AU2018268400A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7658995B2 (ja) 白金耐性癌の治療
US8883737B2 (en) Methods of treating cancer
US20150265723A1 (en) Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
JP2014515390A (ja) Ｐｉ３ｋ阻害剤化合物を用いた中皮腫の治療法
TW201306837A (zh) 使用ｐｉ３ｋ抑制劑及ｍｅｋ抑制劑用於治療癌症之組成物及方法
BRPI0617949A2 (pt) método de tratamento de cáncer de mama usando 17-aag ou 17-ag ou um pró-fármaco de qualquer um dos mesmos em combinação com um inibidor de her2
Sobol et al. Vasopressin analog [V4Q5] dDAVP exerts cooperative anticancer effects in combination with low-dose 5-fluorouracil on aggressive colorectal cancer models
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
EP2575459A1 (en) Cancer treatment with wortmannin analogs
CA3062552C (en) Platinum-resistant cancer treatment
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
US20250177352A1 (en) Combination treatment for cancer
CN101528705A (zh) 17-aag或17-ag或两者之一的前药与her2抑制剂联用治疗乳腺癌的方法
WO2023072043A1 (zh) 治疗肿瘤的联用药物
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
CN114432438A (zh) 喹啉衍生物与pd-1单抗的药物组合
MX2008005467A (en) Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
HK1226957A1 (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240920

R150 Certificate of patent or registration of utility model

Ref document number: 7627393

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150